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Recent sequencing studies demonstrated the MYD88 L265P mutation in more than
70% of primary central nervous system lymphomas (PCNSL), and the clinical signifi-
cance of this mutation has been proposed as diagnostic and prognostic markers in
PCNSL. In contrast, mutational analyses using cell-free DNAs have been reported in
a variety of systemic lymphomas. To investigate how sensitively the MYD88 L265P
mutation can be identified in cell-free DNA from PCNSL patients, we carried out
droplet digital PCR (ddPCR) and targeted deep sequencing (TDS) in 14 consecutive
PCNSL patients from whom paired tumor-derived DNA and cell-free DNA was
available at diagnosis. The MYD88 L265P mutation was found in tumor-derived
DNA from all 14 patients (14/14, 100%). In contrast, among 14 cell-free DNAs eval-
uated by ddPCR (14/14) and TDS (13/14), the MYD88 L265P mutation was
detected in eight out of 14 (ddPCR) and in 0 out of 13 (TDS) samples, implying
dependence on the detection method. After chemotherapy, the MYD88 L265P
mutation in cell-free DNAs was traced in five patients; unexpectedly, the mutations
disappeared after chemotherapy was given, and they remained undetectable in all
patients. These observations suggest that ddPCR can sensitively detect the MYD88
L265P mutation in cell-free DNA and could be used as non-invasive diagnostics, but
may not be applicable for monitoring minimal residual diseases in PCNSL.
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1 | INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is a rare subtype
of diffuse large B-cell lymphoma (DLBCL) that arises within the brain
or eyes. PCNSL accounts for up to 2%-3% of primary malignant brain
tumors and less than 1% of non-Hodgkin lymphomas (NHL) in adults.1
Almost all PCNSL patients undergo invasive surgical procedures for
appropriate diagnosis. However, histological diagnosis of PNCSL is
sometimes difficult because of deep brain structure involvement.
Therefore, there is a need for a more reliable and minimally invasive
biomarker detection method aiding the diagnosis of PCNSL.
Recently, circulating tumor DNAs, which are fragmented DNAs
released through the apoptotic process of tumor cells, in plasma and
serum have received attention as materials for non-invasive
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diagnosis.2 Many genetic alterations identified in tumors have been
used to detect circulating tumor DNAs in patients with both solid
cancers and hematological malignancies.2-4
Whole exome and targeted sequencing studies have determined
the genetic profiles of PCNSL. Notably, mutations in genes associ-
ated with the nuclear factor kappa B (NF-jB) and B-cell receptor sig-
naling pathways are highly frequent in PCNSL.5-12 In particular, the
MYD88 L265P mutation was found in 38%-85.4% of PCNSL patients
but never in those with non-hematological brain tumors, suggesting
that this mutation is useful for differential diagnosis of PCSNL
among central nervous system (CNS) tumors.5-12
Herein, we examined how sensitively the MYD88 L265P muta-
tion is detected in cell-free DNAs in PCNSL patients at diagnosis
and during the disease course.
2 | MATERIALS AND METHODS
2.1 | Patient characteristics
From October 2014 to June 2017, a total of 30 consecutive patients
diagnosed with PCNSL were identified in the clinical records at the
University of Tsukuba Hospital. Sixteen patients were excluded from
this study because CNS tumor or serum samples before treatment
were not available. The remaining 14 patients were analyzed in a
retrospective way (Table S1).
This retrospective study was approved by the institutional review
board of University of Tsukuba Hospital. Samples were provided in
accordance with the “Guidelines for clinical measurement and diag-
nosis technology improvement project”. The guidelines are promoted
by Tsukuba Medical Laboratory of Education and Research Center
and University of Tsukuba Hospital, Japan.
2.2 | Serum and plasma collection
Serum samples were collected before first-line therapy in all 14
patients. A plasma sample before treatment was available in one
patient only (TP103). Serial serum samples were preserved during the
clinical courses from five patients (TP87, TP89, TP90, TP92, and
TP99). Cell-free DNAs were extracted from 700 to 3000 lL serum or
plasma using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden,
Germany). Genomic DNAs were also extracted from 14 formalin-fixed,
paraffin-embedded (FFPE) CNS tumor samples using the FFPE tissue
Kit (Qiagen). Final DNAs were dissolved in 30-50 lL AVE buffer (Qia-
gen, Hilden, Germany) and were stored at 20°C until use.
2.3 | ddPCR assay
Droplet digital polymerase chain reaction (ddPCR) reagents and
Primer/probe mix for MYD88 L265P were purchased from Bio-Rad
(Hercules, CA, USA). The 20 lL PCR mix, composed of 10 lL of 29
ddPCR Supermix for Probes (No dUTP) (Bio-Rad), 1 lL ddPCR Muta-
tion Assay (Bio-Rad) that used an amplicon of 65 nt, 5 lL ultra pure
distilled water and 4 lL cell-free DNA was loaded into sample wells
of an 8-channel disposable droplet generator cartridge (Bio-Rad).
Additional 70 lL droplet generation oil (Bio-Rad) was loaded into
the oil well for each channel. After droplet generation, droplets were
transferred carefully into a 96-well PCR plate. The plate was heat-
sealed with the PX1 PCR Plate Sealer (Bio-Rad) and proceeded to
thermal cycling. Amplification was carried out on the 20 lL reaction
mixture on the QX200 Droplet digital PCR system (Bio-Rad).
After PCR, the 96-well PCR plate was subjected to the QX-200
droplet reader (Bio-Rad). ddPCR data were analyzed by QuantaSoft
analysis software (Bio-Rad) that accompanied the droplet reader. In
our analyses, MYD88 L265P mutation-specific signals were gener-
ated in the FAM channel, whereas MYD88 wild-type signals were in
the HEX channel.
2.4 | Targeted deep sequencing
Targeted deep sequencing (TDS) was carried out on Ion Torrent PGM
platform (Thermo Fisher Scientific, Waltham, MA, USA) for MYD88
L265P mutation as previously described with minor modifications.13
The Ion Plus Fragment Library Kit (Thermo Fisher Scientific) was used
to prepare the libraries according to the recommended protocol for
libraries of short amplicons.
Primers were designed to amplify the genomic regions encoding
codon 265 in MYD88 (Table S2). PCR was carried out in a final vol-
ume of 10 lL with tumor-derived DNAs and cell-free DNAs,
5 nmol/L primers, and KOD Neo reagents (Toyobo, Osaka, Japan).
The PCR protocol was as follows: 10 minutes at 95°C, followed by
39 cycles of 15 seconds at 95°C and 60 seconds at 60°C. Then,
PCR amplicons were ligated to barcode adapters and P1 adapters,
and amplified to generate libraries. Quantification of the amplified
libraries was done by quantitative PCR with the Ion Library Quantifi-
cation kit according to the manufacturer’s instructions (Thermo
Fisher Scientific). The libraries were then subjected to deep
sequencing on Ion Torrent PGM with the Ion 318 chip according to
the standard protocol for 300 base pair single-end reads (Thermo
Fisher Scientific). The data were analyzed by Variant caller 5.2
(Thermo Fisher Scientific). The sequencing variations were adopted
as mutations when frequencies were higher than 2% for tumor-
derived DNA and 0.2% for cell-free DNA.
2.5 | Statistical analysis
Statistical analysis was conducted using the EZR software.14 We
used two-sided tests in all calculations. P-value ≤ .05 was considered
statistically significant.
3 | RESULTS
3.1 | Validation of the ddPCR assay and TDS for
detecting the MYD88 L265P mutation
The signal emitted by the MYD88 L265P mutation was clearly distin-
guished from that by wild-type DNA in a 2D fluorescent amplitude
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plot (Figure S1). Lower limits of detection (LOD) and quantification
(LOQ) in ddPCR were determined using serial dilutions of DNA with
the MYD88 L265P mutation. We chose a frozen tissue-derived DNA
in which AmpliSeq measured 24.2% variant allele frequency (VAF) at
the depth of 1920. This sample was serially diluted at 1/4 each
down to (1/4)7, by mixing with the copy number-adjusted DNA
without MYD88 L265P mutation. All dilutions were then applied to
ddPCR. Mutation ratio was calculated for each sample by Quanta-
Soft and plotted (Figure 1).
In the 1/4 (corresponding to 6.05% by calculation), (1/4)2
(1.5125%), (1/4)3 (0.378125%), (1/4)4 (0.09453125%), (1/4)5
(0.0236328125%), dilutions, fractional abundance (referring to the pro-
portion of mutated DNA by QuantaSoft) measured by ddPCR was
8.3%, 3.1%, 1.0%, 0.2% and 0.1%. After being converted to log-log
scale, data showed precision and linearity down to a dilution of 0.024%;
this material corresponded to a fractional abundance of 0.1% (coeffi-
cient of determination [R2] was .994). The positive control diluted to (1/
4)6 (0.005908203125%) was judged as positive by ddPCR, whereas the
fractional abundance was 0.07%, implying that the quantification was
inaccurate (Figure 1). All dilutions less than (1/4)6 showed 0%.
Based on this result, the LOQ of ddPCR was defined as 0.024%
with a fractional abundance of 0.1%. The LOD could be lowered to
0.0059% with a fractional abundance of 0.07%.
The same dilution series was also applied to amplicon-based
sequencing at the approximate depth of 20 000 reads and the muta-
tion ratio was plotted (Figure 2). In the 1/4 (corresponding to 6.05%
by calculation), (1/4)2 (1.5125%), and (1/4)3 (0.378125%) dilutions,
VAF measured by amplicon-based sequencing was 7.2%, 2.7%, and
0%. All dilutions less than (1/4)3 showed 0%. Based on this, the cut-
off value was determined at 1.51%. After being converted to log-log
scale, data showed precision and linearity down to a dilution of
1.51% (R2 was 1; Figure 2).
Therefore, LOQ and LOD of TDS were defined as 1.51% with a
VAF of 2.7%.
3.2 | MYD88 L265P mutation in tumor-derived
DNA
We examined the MYD88 L265P mutation in tumor-derived DNA
prepared from 14 PCNSL patients by ddPCR and TDS (Table 1). In
this cohort, MYD88 L265P mutation was found in all patients (14/
14, 100%; range of VAF, 10.5%-87.0%) and mean depths for the
mutation in tumor-derived DNAs were 16868x to 19993x (Table 1).
3.3 | Detection of the MYD88 L265P mutation in
cell-free DNAs at diagnosis
Amounts of cell-free DNA, prepared from 1 mL serum or plasma
that was collected before treatment, ranged from 107 ng to
2410 ng (Figure 3).
The MYD88 L265P mutation was detected by ddPCR in eight
out of 14 serum-derived cell-free DNAs at diagnosis (Figure 1;
Figure S1). Among six negative subjects, we prepared plasma-derived
cell-free DNA from only 1; the mutation was also undetectable in
this preparation (TP103, Table S3). VAF of the MYD88 L265P muta-
tion in cell-free DNAs was significantly lower than those of the
tumors (mean, 0.34% [range, 0.1%-0.69%] vs 48.5% [10.5%-87%],
P < .001). Thirteen samples, except for one sample of TP100
because the amount of DNA in this sample was not sufficient, were
also evaluated by TDS. Mean depths for MYD88 L265P in cell-free
DNA were 12 560x to 19 996x. In this method, the mutations were
not detected at all irrespective of whether or not they were detect-
able by ddPCR.
Presence of mutations in cell-free DNAs was not significantly
associated with laboratory data, such as lactate dehydrogenase
(LDH) (P = .360) and soluble interleukin-2 receptor (sIL2R) (P = .354)
levels, concentrations of cell-free DNAs (P = .105), tumor sizes
(P = .611) and clinical outcomes (OS, P = .386; PFS, P = .629).
F IGURE 1 Sensitivity of our droplet digital PCR (ddPCR) assay.
DNA with MYD88 L265P mutation was mixed with DNA without
the mutation at the concentrations indicated on the horizontal axis.
All diluted samples were individually subjected to ddPCR. Fractional
abundance (mutation ratio calculated by QuantaSoft) for each
sample is plotted
F IGURE 2 Sensitivity of our targeted deep sequencing (TDS)
assay. DNA with MYD88 L265P mutation was mixed with DNA
without the mutation at the concentrations indicated on the
horizontal axis. All diluted samples were individually subjected to
TDS assay. Variant allele frequency for each sample is plotted
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3.4 | MYD88 L265P mutation in cell-free DNAs
during the disease course
To investigate whether the MYD88 L265P mutation in cell-free
DNAs is a useful marker for estimating disease course, such as
remission and/or progression of disease (PD), we analyzed the
MYD88 L265P mutation in cell-free DNAs during and after
chemotherapies in five patients who showed positivity of the
MYD88 L265P mutation in cell-free DNAs at diagnosis.
Patients TP92 and TP99 received the modified EORTC regimen15
and the R-MPV regimen,16 respectively. They obtained complete
remission (CR) during the observation period. However, the mutations
were not detected at all throughout the treatment courses (Figure 4).
In two patients (TP87 and TP89), once achieving CR, lymphomas
relapsed at 3 months (TP89) and 12 months (TP87) after completion
of the therapies. In TP89, relapse occurred in intraocular tissues
without reappearance of a tumor in the CNS. In TP87, tumor size at
the time of progression was smaller than that at diagnosis
(10 9 15 mm vs 42 9 55 mm). In contrast, TP90 was treated by
the modified EORTC regimen, but it was abandoned after induction
therapy because of PD. Tumor size at the time of progression was
bigger than that at diagnosis (56 9 70 mm vs 37 9 46 mm). In
these patients, the MYD88 L265P mutation was not detected in cell-
free DNAs despite disease progress after the relapse (Figure 4).
4 | DISCUSSION
The present study demonstrated that the MYD88 L265P mutation
was detected by the ddPCR assay in 57.1% of cell-free DNAs of
PCNSL patients at diagnosis. Further analysis is required to deter-
mine the actual detection rate of this mutation in cell-free DNAs of
PCNSL. Consistent with the previous report on liquid biopsies, our
results confirmed that the ddPCR assay is a reliable method to
detect mutations in cell-free DNAs and has an advantage over TDS
TABLE 1 Targeted sequencing of MYD88 L265P for 14 PCNSL samples
Mutation ratio of MYD88 L265P (%)
Tumors Cell-free DNAs in serum
NGS
ddPCR
NGS
ddPCR
VAF (%)
Reads showing the
mutation/total reads FA (%) VAF
Reads showing the
mutation/total reads FA (%)
TP73 43.2 8584/19870 ND 0 0/19996 0
TP87 65.5 13070/19954 ND 0 0/19930 0.40
TP89 35.1 6979/19882 ND 0 0/19981 0.19
TP90 40.9 8137/19895 ND 0 0/19980 0.09
TP92 53.3 10534/19763 ND 0 0/19985 0.10
TP94 61.3 12233/19956 ND 0 0/19948 0.38
TP95 36.4 7230/19862 ND 0 0/19963 0.14
TP96 56.1 11122/19825 ND 0 0/19972 0.47
TP98 88.7 17736/19993 87 0 0/19987 0
TP99 56.6 11299/19974 55.9 0 0/19994 0.69
TP100 75.2 15025/19980 79 ND ND 0
TP101 9.2 1844/19988 10.5 0 0/12560 0
TP102 43 7260/16868 38.3 0 0/19991 0
TP103 19.7 3928/19973 17.1 0 0/19989 0
ddPCR, droplet digital PCR; FA, fractional abundance; ND, not done; NGS, next-generation sequencing; PCNSL, primary central nervous system lym-
phoma; VAF, variant allele frequency.
F IGURE 3 Concentrations of cell-free DNAs of primary central
nervous system lymphoma (PCNSL). Distribution of the cell-free
DNA concentrations in serum in patients with PCNSL is shown by
plots. The y-axis has a log scale
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in detecting very small numbers of mutation copies, avoiding biases
during the PCR procedures that happen in TDS.
Nakamura et al reported that almost all PCNSL had MYD88 and
CD79B mutations, whereas they were not detected in glioblastomas
(GBM).12,17 These mutations may serve as a genetic hallmark that
help a differential diagnosis among these two most common malig-
nant brain tumors.12
In our analysis, concentration of cell-free DNAs in PCNSL was
107-2410 ng/mL. This estimation implies a much higher level than
that of cell-free DNA prepared from healthy volunteers, which were
reported to be 1-10 ng/mL.18 Also, the estimated range appears to
be higher than that of cell-free DNA amounts in patients with non-
hematological neoplasms, such as colorectal, lung, and breast cancer
(range 0.5-1980 ng/mL).19–21 However, this range of concentration
was lower than that of cell-free DNAs in patients with systemic lym-
phomas (range 100-14 180 ng/mL).22,23
In our analysis, the MYD88 L265P mutation was not detected in
cell-free DNAs by TDS. However, Fontanilles et al recently reported
that a variety of somatic mutations specific to CNS tumors, including
MYD88 L265P mutation, were detected in cell-free DNAs of PCNSL
patients by TDS.24 In their study, VAF of the MYD88 L265P muta-
tion in cell-free DNAs was magnitudinally higher than those in our
study (mean, 4.7% vs 0.34%).24 The higher VAFs in their study may
be a major reason why Fontanilles et al succeeded in the detection
of mutations by TDS. In their study, materials used for extraction of
cell-free DNAs were plasma, whereas ours were serum. This differ-
ence might explain the discordant VAF, despite the fact that our
analysis of one paired cell-free DNA prepared from serum and
plasma failed to demonstrate it. Another potential cause of the dis-
cordance could be the bias among the cohorts. Several previous
studies have shown that cell-free DNA in several types of lym-
phomas could also be a surrogate marker for tumor burden.25-27 If
the tumor burden in our cohort was less than in others because of
the early setting of biopsies, the discordance might be explained.
Diagnosis and identifying minimal residual diseases (MRD) by
using cell-free DNA have also been examined in DLBCL: cancer per-
sonalized profiling by deep sequencing (CAP-seq) and high-through-
put sequencing identifying clonotypic Ig rearrangement using cell-free
DNA were shown to be useful for early detection of relapse.21,25,26
Recently, we showed that gene mutations specific to angioimmuno-
blastic T cell lymphoma in cell-free DNAs could be useful as sensitive
markers for circulating tumor DNAs and might be applicable for non-
invasive monitoring of MRD.27 However, in the current study, the
MYD88 L265P mutation was not detected in cell-free DNAs even in
the PD state. Our results suggest that circulating tumor DNAs in
patients with PCNSL may not be applicable to monitoring the disease
course of PCNSL, although those in patients with systemic lym-
phomas were shown to be useful for monitoring of MRD.26,27 It
remains to be elucidated why the MYD88 L265P mutation was unde-
tectable in the PD state. Tumor size may not explain the reason, con-
sidering that tumor size in the CNS at the time of disease progression
was bigger than that at diagnosis in a case (TP 90). Moreover, there
was a possibility that the MYD88 L265P mutation-negative clone may
expand in relapsed tumors or that cell-free DNA may not circulate in
peripheral blood after chemotherapy. Unfortunately, we analyzed the
course of MYD88 L265P mutation in cell-free DNAs in five cases
only. Further analysis will enable us to determine whether MYD88
mutations are applicable for detecting MRD.
To our knowledge, this is the first study for the detection of gene
mutations in cell-free DNAs in PCNSL patients using the ddPCR
F IGURE 4 Mutation ratio in cell-free DNAs and disease course. A, Patients who maintained complete remission (CR). B, Patients who
progressed during or after the therapy
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assay. Ratio of detection of the MYD88 L265P mutation in cell-free
DNA among the mutation-positive patients was 57%. The ddPCR-
based detection of the MYD88 L265P mutation in cell-free DNA may
serve as a useful method for non-invasive diagnosis of PCNSL.
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